Teva: Biosimilars In The US Will Become Like Complex Generics :: Generics Bulletin
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States | Business Wire
Teva launches biosimilar to Roche's Rituxan
Home - TRUXIMA® (rituximab-abbs) HCP site.
Teva launches rituximab biosimilar Truxima in US
Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US
Teva teams up on biosims with Celltrion three years after its Lonza JV divorce | Fierce Biotech
Drug Channels: The Booming Biosimilar Market of 2020
Drug Channels: The Booming Biosimilar Market of 2020
Teva Signs an Exclusive Commercialization Agreement with Bioeq for FYB201 ( biosimilar- ranibizumab)
Celltrion's Truxima (rituximab-abbs) Biosimilar Product Profile
Roche faces prospect of second Rituxan biosimilar in US - PMLiVE
Biosimilars encircle Rituxan, US debates innovator exclusivity | Nature Biotechnology
About Biosimilars - TRUXIMA® (rituximab-abbs)
Teva launches Rituxan biosimilar for Rheumatoid Arthritis - Globes
FDA panel unanimously backs Celltrion's Rituxan biosimilar | Fierce Pharma
Pfizer's rituximab biosimilar gets late-stage trial boost
Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA
Top developments in biosimilars during 2019 - GaBI Journal
The U.S. Biosimilars Market: Shaking The “Laggard” Label | Contract Pharma
FDA approves Celltrion, Teva's Rituxan biosimilar, but with a narrow label - MedCity News
Teva, Celltrion get FDA nod for biosimilar to Roche's cancer drug Rituxan
Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S. | Fierce Pharma
